Results 281 to 290 of about 934,569 (347)

DOUBLE-TRACK RECOVERY STRATEGY TO ADDRESS THE SUSTAINABLE RECOVERY FOR COMMUNITIES IMPACTED BY THE SEMERU ERUPTION, INDONESIA

Mohamad Mambaus Suud, Syamsul Bachri, Sumarmi Sumarmi, I Komang Astina, Anisatu Nadhiroh   +4 more
openalex   +2 more sources

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Longitudinal assessment of oral intake adequacy and nutrition-impacted symptoms in patients undergoing allogeneic hematopoietic stem cell transplantation. [PDF]

Front Nutr
Qin L, Li R, Wu J, He Y.
europepmc   +1 more source

REVIEW OF MANDIBULAR ANESTHESIA TECHNIQUES IN THE EXTRACTION OF IMPACTED THIRD MOLARS

Mendoza, Fabian Andrés Pinargote, Monga, William Kluyvert Huilca, Zapata, Zuly, Tenicela, Mishel Estefanía Añazco, Teran, Guillermo Alberto Lanas   +4 more
openalex   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Interdisciplinary Management of an Infected Dentigerous Cyst Associated with an Impacted Maxillary Canine: A Case Report with a 6-year Follow-up. [PDF]

Int J Clin Pediatr Dent
Dutta K, Shetty YR, Nayak PP, Bhandary M, Ananthu H, Rai K, Nair MR.   +6 more
europepmc   +1 more source

Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition

Molecular Oncology, EarlyView.
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, Hideki Enokida   +10 more
wiley   +1 more source

Evaluation of medical physics resident well-being and satisfaction across multiple residency programs. [PDF]

J Appl Clin Med Phys
Burmeister JW, Biswal NC, Harms J, Paxton AB, Boggula R.   +4 more
europepmc   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source